Author:
Karadeniz-Yildirim Ayşe,Ozkorucuklu Suat,Tanyildizi-Kokkulunk Handan,Demir Mustafa,Yasar Dogan
Reference27 articles.
1. Kouri, B.E., Abrams, R.A., Al-Refaie, W.B., et al., ACR appropriateness criteria radiologic management of hepatic malignancy, J. Am. Coll. Radiol., 2012, vol. 13, no. 3, pp. 265–273.
2. Walker, L.A., Radioactive yttrium 90: A review of its properties, biological behavior, and clinical uses, Acta Radiologica: Therapy, Physics, Biology, 1963, vol. 2, pp. 302–314.
3. Sarrut, D., Bardiès, M., Boussion, N., Freud, N., Jan, S., Létang, J.-M., Loudos, G., Maigne, L., Marcatili, S., Mauxion, T., Papadimitroulas, P., Perrot, Y., Pietrzyk, U., Robert, C., Schaart, D.R., Visvikis, D., and Buvat, I., A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications, Med. Phys., 2014, vol. 41, no. 6, part 1, p. 064301. https://doi.org/10.1118/1.4871617
4. Dezarn, W., Cessna, J., DeWerd, L., et al., Recommendations of the American association of physicists in medicine on dosimetry, imaging, and quality assurance procedures for 90y microsphere brachytherapy in the treatment of hepatic malignancies., Med. Phys., 2011, vol. 38, pp. 4825–4845.
5. Forrest, B.B., MCNP—A general Monte Carlo n-particle transport code, Version 5 LA-UR-03-1987, Los Alamos: Los Alamos National Laboratory, 2003.